Luxiq

(Betamethasone Sodium Phosphate)

ApprovedSmall molecule

SSchering-Plough

Luxiq is one of 24 small molecule programs targeting Hypoglycemia. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

HypoglycemiaActive, not recruiting

HypoglycemiaApproved

Active, not recruiting

Competition

Competitive Landscape

26 competitors in Hypoglycemia

#DrugCompanyPhaseTrials

Aldactone

Pfizer

Approved

1 2

NOVOLIN R

Novo Nordisk

Approved

1 3

Avelox

Narcan

2 5

Symlin

AstraZeneca

Approved

1 6

Proglycem

Teva

Approved

1 7

Januvia

ZZydus Therapeutics Inc.

Approved

1 8

Luxiq

SSchering-Plough

Approved

1 9

Reglan

IIstituto Clinico Humanitas

Phase 2

1 10

Avexitide

AAmylyx Pharmaceuticals Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Antenatal Corticosteroids1 trial

Effect of Antenatal Corticosteroids on Neonatal Morbidity.

Completed·—·N/A·NCT03446937·150 enrolled

Hypoglycemia1 trial

Late Preterm Corticosteroids and Neonatal Hypoglycemia

Unknown status·UUniversity of Southern California·Phase 4·NCT04869709·210 enrolled

Treatment1 trial

Comparison of 2 Doses of Corticosteroid Subacromial Injections for the Treatment of Painful Shoulder

Withdrawn·HHaEmek Medical Center, Israel·N/A·NCT00914836

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

UTICORT

NDA NDA018089

Jan 1, 1982

UTICORT

NDA NDA017528

Jan 1, 1982

VALISONE

NDA NDA016932

Jan 1, 1982

VALISONE

NDA NDA016740

Jan 1, 1982

CELESTONE

NDA NDA014215

Jan 1, 1982

CELESTONE

NDA NDA014762

Jan 1, 1982

UTICORT

NDA NDA016998

Jan 1, 1982

VALISONE

NDA NDA016322

Jan 1, 1982

CELESTONE

NDA NDA017561

Jan 1, 1982

UTICORT

NDA NDA017244

Jan 1, 1982

CELESTONE

NDA NDA012657

Mar 24, 1983

BETA-VAL

NDA NDA018642

Jun 30, 1983

BETADERM

NDA NDA018839

Aug 31, 1983

BETAMETHASONE VALERATE

NDA NDA018866

Aug 31, 1983

BETAMETHASONE VALERATE

NDA NDA018861

Aug 31, 1983

BETAMETHASONE VALERATE

NDA NDA018860

Aug 31, 1983

BETATREX

NDA NDA018862

Aug 31, 1983

BETAMETHASONE VALERATE

NDA NDA018870

Aug 31, 1983

BETATREX

NDA NDA018867

Aug 31, 1983

BETAMETHASONE VALERATE

NDA NDA018865

Aug 31, 1983

BETAMETHASONE VALERATE

NDA NDA018864

Aug 31, 1983

BETATREX

NDA NDA018863

Feb 28, 1999

LUXIQ

NDA NDA020934

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Betamethasone Sodium Phosphate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Betamethasone Sodium Phosphate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Betamethasone Sodium Phosphate. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA020934). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Schering-Plough company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: SSchering-Plough

Luxiq

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Antenatal Corticosteroids1 trial

Hypoglycemia1 trial

Treatment1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News